Arcus scores $305M regional development pact with Taiho; Shire, Shionogi tout PhIII ADHD study

⇨ Terry Rosen’s Arcus Biosciences has scored a $35 million development deal with Taiho in exchange for regional rights to its cancer immunotherapies. Hayward, CA-based Arcus gets the $35 million in cash spread out over three years, with another $275 million in milestones laid out for successful work. Taiho’s option for Asia is stretched out over five years.

Shire and its partner in Japan, Shionogi, say their Phase III study of Intuniv (guanfacine hydrochloride prolonged release) in adult patients with attention deficit hyperactivity disorder (ADHD) in Japan has racked up positive topline results, meeting the primary endpoint.

PPD has inked a deal to manage Treos Bio’s first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. The study will be conducted in the United States and Europe.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->